Page, David B. http://orcid.org/0000-0001-9264-4628
Pucilowska, Joanna
Chun, Brie http://orcid.org/0000-0001-7520-8365
Kim, Isaac
Sanchez, Katherine
Moxon, Nicole http://orcid.org/0000-0003-4376-9082
Mellinger, Staci
Wu, Yaping
Koguchi, Yoshinobu http://orcid.org/0000-0002-5733-5755
Conrad, Valerie
Redmond, William L. http://orcid.org/0000-0002-2572-1731
Martel, Maritza
Sun, Zhaoyu
Campbell, Mary B.
Conlin, Alison
Acheson, Anupama
Basho, Reva
McAndrew, Philomena
El-Masry, Mary
Park, Dorothy
Bennetts, Laura
Seitz, Robert S.
Nielsen, Tyler J. http://orcid.org/0000-0002-9576-2838
McGregor, Kimberly
Rajamanickam, Venkatesh
Bernard, Brady
Urba, Walter J.
McArthur, Heather L. http://orcid.org/0000-0002-0201-3871
Funding for this research was provided by:
Merck & Co., Inc. | Merck Sharp and Dohme
Providence Foundations of Oregon
Article History
Received: 11 August 2022
Accepted: 21 April 2023
First Online: 21 June 2023
Competing interests
: D.B.P.—speaker’s bureau honoraria- Genentech, Novartis, Clinical Care Options, Oncocyte; Research funds: WindMIL, Brooklyn Immunotherapeutics, Merck, Bristol-Myers Squibb, IMV; consulting fees: Merck, Gilead, Biotheranostics, Puma, Lilly, Sanofi, NGM Bio, Sanford Burnam Prebys, AstraZeneca. J.P.—none. B.C.—none. I.K.—none. K.S.—none. N.M.—none. S.M.—none. Y.W.—none. Y.K.—Research support from Bristol Myers Squibb (BMS), GlaxoSmithKline, Shimadzu. V.C.—none. W.L.R.—Please update this: Research support from Bristol-Myers Squibb, GlaxoSmithKline, MiNA Therapeutics, Inhibrx, Veana Therapeutics, Shimadzu, OncoSec Medical, Turn Biotechnologies, CanWell Pharma, Galecto, and Calibr. Patents/Licensing fees: Galectin Therapeutics. Advisory Boards: Medicenna, Vesselon. Z.S.—acquisition of data. M.M.—none. M.C.—acquisition of data. A.C.—none. A.A.—None. R.B.—Institutional research funding from Seattle Genetics, Merck, Takeda, Pfizer; Consulting role: Biotheranostics, Pfizer, AstraZeneca, Seattle Genetics, Gilead, Novartis; Speaker: Eli Lilly, Seattle Genetics, WebMD, MJH Healthcare. P.M.—none. M.E.-M.—none. D.P.—none. I.E.C.—none. L.B.—none. R.S.S.—Employment: Oncocyte. T.J.N. – Employment: Oncocyte. K.M.- Employment: Oncocyte. V.R.—None. B.B.—None. W.J.U.—Safety advisory board: Astra Zeneca. H.L.M.—Research support: Merck, Lilly, BMS. Advisory/consultancy Merck, Lilly, Spectrum Pharmaceuticals, Amgen, Immunomedics, Pfizer, Genentech, BMS, Genomic Health, ZIOPHARM Oncology; Travel/expenses: Merck, Spectrum Pharmaceuticals, Lilly, Amgen, Immunomedics, Pfizer, Genentech Puma Biotechnology; Speaker Bureau: Lilly. Institutional funding: Merck, Lilly, BMS, ZIOPHARM Oncology.